Delayed atomoxetine or fluoxetine treatment coupled with limited voluntary running promotes motor recovery in mice after ischemic stroke

Faisal F. Alamri1, †, Abdullah Al Shoyaib1, Nausheen Syeera1, Anisha Paul1, Srinidhi Jayaraman1, Serob T. Karamyan2, Thiruma V. Arumugam3, Vardan T. Karamyan1, 4, *

Abstract

Currently, there is an unmet need for treatments promoting post-stroke functional recovery. The aim of this study was to evaluate and compare the dose-dependent effect of delayed atomoxetine or fluoxetine therapy (starting on post-stroke day 5), coupled with limited physical exercise (2 hours daily voluntary wheel running; post-stroke days 9 to 42), on motor recovery of adult male mice after photothrombotic stroke. These drugs are selective norepinephrine or serotonin reuptake inhibitors indicated for disorders unrelated to stroke. The predetermined primary end-point for this study was motor function measured in two tasks of spontaneous motor behaviors in grid-walking and cylinder tests. Additionally, we quantified the running distance and speed throughout the study, the number of parvalbumin-positive neurons in the medial agranular cortex and infarct volumes. Both sensorimotor tests revealed that neither limited physical exercise nor a drug treatment alone significantly facilitated motor recovery in mice after stroke. However, combination of physical exercise with either of the drugs promoted restoration of motor function by day 42 post-stroke, with atomoxetine being a more potent drug. This was accompanied by a significant decrease in parvalbumin-positive inhibitory interneurons in the ipsilateral medial agranular cortex of mice with recovering motor function, while infarct volumes were comparable among experimental groups. If further validated in larger studies, our observations suggest that add-on atomoxetine or fluoxetine therapy coupled with limited, structured physical rehabilitation could offer therapeutic modality for stroke survivors who have difficulty to engage in early, high-intensity physiotherapy. Furthermore, in light of the recently completed Assessment of Fluoxetine in Stroke recovery (AFFINITY) and Efficacy of Fluoxetine-a randomised Controlled Trial in Stroke (EFFECTS) trials, our observations call for newly designed studies where fluoxetine or atomoxetine pharmacotherapy is evaluated in combination with structured physical rehabilitation rather than alone. This study was approved by the Texas Tech University Health Sciences Center Institutional Animal Care and Use Committee (protocol # 16019).

Key Words: drug repurposing; neural repair; physical exercise; physiotherapy; post-stroke recovery; pre-clinical trial; FLAME trial; selective norepinephrine reuptake inhibitor; selective serotonin reuptake inhibitor; stroke pharmacotherapy

Funding: This work was partly supported by a National Institutes of Health Research Grant to VTK (1R01NS106879).

How to cite this article: Alamri FF, Al Shoyaib A, Syeera N, Paul A, Jayaraman S, Karamyan ST, Arumugam TV, Karamyan VT (2021) Delayed atomoxetine or fluoxetine treatment coupled with limited voluntary running promotes motor recovery in mice after ischemic stroke. Neural Regen Res 16(7):1244-1251.
Introduction

The unmet need for treatments promoting functional recovery after stroke has led to an increased research focus on understanding neural repair and post-stroke recovery mechanisms to develop restorative therapies (Bernhardt et al., 2017b; Yang et al., 2020). These strategies modulate and/or enhance the cellular and molecular mechanisms of neural plasticity (Murphy and Corbett, 2009; Carmichael, 2016; Hatakeyama et al., 2020), with physiotherapy being the most reproduced intervention with positive impact on post-stroke recovery in preclinical and clinical studies (Krackauer et al., 2012; Bernhardt et al., 2016). Notably, physical rehabilitation is mostly effective at high intensity and early after stroke—a period when there is enhanced neuroplasticity in the brain (Krackauer et al., 2012). Unfortunately, most stroke survivors are unable to meet the requirement of high-intensity and early rehabilitation, because of which their recovery is usually very limited (Krackauer et al., 2012; Nicholson et al., 2013). One potential approach to overcome this problem maybe through add-on pharmacological therapy (Cramer, 2015; Carmichael, 2016).

To this end, the aim of this study was to evaluate the effect of delayed pharmacological therapy by atomoxetine or fluoxetine, coupled with limited physical rehabilitation, on recovery of motor function in mice after ischemic stroke. Atomoxetine is a selective norepinephrine reuptake inhibitor, which elevates synaptic levels of norepinephrine and is approved for management of attention deficit hyperactivity disorder (Christman et al., 2004), whereas fluoxetine is a selective serotonin reuptake inhibitor, which elevates synaptic levels of serotonin and is indicated for management of major depression (Wong et al., 1995).

Our study is the first to directly evaluate and compare the dose-dependent effect of delayed atomoxetine or fluoxetine therapy (starting on post-stroke day 5), coupled with limited physical rehabilitation (2 hours daily voluntary wheel running post-stroke days 9 to 42), on recovery of motor function in the mouse photothrombotic model of ischemic stroke. We applied rigorous and clinically relevant experimental design and analysis standards to test the efficacy of these therapeutic combinations in adult male mice. The predetermined primary end-point for this study was motor function measured in two tasks of spontaneous motor behaviors of the forelimb in grid-walking and cylinder tests. Mechanistic elucidation of the observed effects was not an objective of this study, because the pharmacological targets and primary molecular signaling pathways of these drugs have been well-defined (Wong et al., 1995; Christman et al., 2004). Our observations indicate that neither limited physiotherapy nor any of the drug treatments alone significantly facilitate motor recovery in mice after stroke. However, the results of both sensorimotor tests reveal that combination of physical rehabilitation with either of the drugs promotes restoration of motor function by day 42 post-stroke, with atomoxetine being the more potent of the two drugs.

Materials and Methods

Animals

Twelve to fourteen week-old, male CD-1 mice (~36 g at the start of the experiments, n = 105) were used in this study which was approved by the Texas Tech University Health Sciences Center Institutional Animal Care and Use Committee (protocol # 16019, last approved on December 13, 2019). The animals were obtained from Charles River Laboratories (Wilmington, MA, USA) and maintained in standard AAALAC-approved animal care facility with controlled temperature and humidity, 12-hour light/dark cycle and ad libitum access to water and chow. To minimize handling stress, mice were individually handled by investigators ~2 minutes once or twice daily for 1 week before evaluation of their baseline motor function in grid-walking and cylinder tests. Mice were housed individually after stroke, and no animal was eliminated from the study.

Study design and treatments

All experimental group assignments (sham vs. stroke, and treatments within stroke animals) and brain processing by completion of the study (fixing vs. fresh tissue collection) were done randomly (https://www.random.org/lists/) (Jayaraman et al., 2020). Experimental groups (n = 12/group; Figure 1) included “Sham” with no stroke or treatments; “Stroke” with stroke but no treatments; “Vehicle” which had stroke, were treated with saline and physical exercise; “Atomox 0.3” – had stroke, were treated with 0.3 mg/kg atomoxetine and physical exercise; “Atomox 1.0” – had stroke, were treated with 1 mg/kg atomoxetine and physical exercise; “Fluox 3.0” – had stroke, were treated with 3 mg/kg fluoxetine and physical exercise; and “Fluox 10.0” – had stroke, were treated with 10 mg/kg fluoxetine and physical exercise. Atomoxetine and fluoxetine (product # A791400 and F5971100, Toronto Research Chemicals, Toronto, Canada) were injected intraperitoneally (Al Shoyaib et al., 2019), once daily (in saline, 5 mL/kg volume, ~3 hours before the dark cycle started) between post-stroke days 5 to 16. The doses of atomoxetine (0.3 and 1 mg/kg) used in this study are known to increase extracellular concentrations of norepinephrine in the mouse brain (Koda et al., 2010), and are equivalent to the therapeutically effective doses in humans (Ledbetter, 2006). Likewise, the doses of fluoxetine (3 and 10 mg/kg) used in our study elevate extracellular concentrations of serotonin in the mouse brain (Hodes et al., 2010), and are equivalent to its clinically used doses (Rossi et al., 2004). Daily drug treatments were started on post-stroke day 5 to be outside of neuroprotective time-window (inflection point at ~3 days post-stroke (Clarkson et al., 2010)), and completed on day 16. This drug regimen was selected to primarily modulate spontaneous endogenous plasticity and neurorestorative mechanisms at their activation after stroke through the beginning of their decline (Krackauer et al., 2012; Carmichael, 2016; Karamyan, 2021), and to limit the potential side effects of the drugs upon continuous use (Rossi et al., 2004; Ledbetter, 2006).

Physical exercise as a rehabilitative treatment in our study consisted of voluntary wheel running in animal’s home cage for 2 hours at the start of the dark cycle (6 days per week with 1 day off on the day before behavioral tests), starting from post-stroke day 9 until the end of the study. Each running wheel (Innowheel, Innovive, San Diego, CA, USA) was equipped with a custom-designed counter to document the running distance. In addition, running of each animal was video recorded in weeks 4, 5 and 6 to subsequently measure running distance. In addition, running of each animal was video recorded in weeks 4, 5 and 6 to subsequently measure the running speed. In one separate set of experiments, mice were randomly assigned to three groups (n = 7/group) and treated daily with vehicle, atomoxetine (1 mg/kg) or fluoxetine (10 mg/kg) on post-stroke days 5 to 16. Here, the animals did not run on wheels, i.e. no physical rehabilitation, to allow evaluation of the pharmacological intervention alone.

Motor function of the mice was evaluated during the light cycle (8 to 11 a.m.), on post-stroke days 3, 7, 14, 28 and 42. Association of animals with a specific experimental group was blinded from experimenters.

Photothrombotic stroke model

Photothrombosis was induced 3 days after baseline evaluation.
of the motor function as detailed in our earlier publication (Alamri et al., 2018). In brief, the right hemisphere (1.5 mm lateral from Bregma 0) was illuminated through intact skull with cold light (2-mm diameter, 15-minute irradiation, fiber optic illuminator light source with a halogen lamp) starting 5 minutes after intraperitoneal administration of Rose Bengal solution (8 mg/mL, 10 mL/kg) in anesthetized mice maintained at 36.9 ± 0.5°C. After surgery, mice were kept in a recovery chamber (~37°C) for ~1.5 hours followed by individual housing. Sham animals underwent the same procedure except for the light illumination. Throughout the manuscript, the left (contralateral) forelimb of all experimental mice is referred to as ‘affected forelimb’, whereas the right (ipsilateral) forelimb is as ‘unaffected forelimb’.

Grid-walking test
This task was carried out as previously described in our publications (Alamri et al., 2018; Syeera et al., 2019). Footfauls for each forelimb and the total normal steps on an elevated wire grid were counted from a 5-minute video recording. Affected or unaffected footfault percentage was calculated by: number of affected or unaffected forepaw faults/number of normal steps x100.

Cylinder test
This task was also conducted as previously described (Alamri et al., 2018; Syeera et al., 2019). To determine forelimb symmetry in exploratory rearing the use of affected, unaffected or both forelimbs was counted for each rearing in a 5-minute session from a video recording. Forelimb use symmetry index was calculated by: (number of affected forelimb use − number of unaffected forelimb use)/(number of affected forelimb use + number of unaffected forelimb use + number of use of both forelimbs).

Brain collection and infarct size evaluation
On post-stroke day 42, mice were anesthetized with isoflurane (Henry Schein Animal Health, Dublin, OH, USA) to either cardiacly perfuse with phosphate-buffered saline and 4% paraformaldehyde (PFA) for fixing and cryosectioning (immunostaining and infarct evaluation, n = 6/group), or to decapitate and dissect the brain to isolate 1–2 mm of peri-infarct cortex together with infarct core for western blotting (n = 6/group). The brains of PFA-perfused mice were subsequently incubated in 4% PFA overnight, sucrose cryopreserved, and cryosectioned (coronal plane, 50 μm thickness). Cresyl violet staining was carried out following a standard protocol and stained sections were digitized for volumetric analysis (Syeera et al., 2019). Quantification of infarct volume was done by multiplying the lesion area by the thickness of each section plus the distance between sections.

Immunoblotting and immunofluorescence staining
For western blotting, each collected cortical sample was processed according to our published protocol to obtain total cell lysate (Jayaraman et al., 2020), followed by standard SDS-PAGE and immunoblotting as described earlier (Wangler et al., 2012; Rashid et al., 2014). Primary antibodies used were anti-GAP-43 (growth associated protein 43), anti-synaptophysin and anti-lateral (postsynaptic density protein 95) (product# D9CB, D35E4 and D27E11; Cell Signalling Technology, Danvers, MA, USA), whereas the secondary antibody was HRP-conjugated goat anti-rabbit immunoglobulin (product# 170-6515, Bio-Rad Laboratories, Hercules, CA, USA).

For immunostaining, we used free floating cryopreserved brain sections to label parvalbumin containing cells (primary antibody: mouse anti-parvalbumin antibody, 1:150 dilution, overnight incubation at room temperature, product# P3088, Sigma-Aldrich, St. Louis, MO, USA; secondary antibody, donkey AlexaFluorTM 488 IgG, 1:2000 dilution, overnight incubation at room temperature, product# A21202, Thermo Fisher Scientific, Waltham, MA, USA) following standard procedures (Jayaraman et al., 2020). Fluorescence microscopic images were acquired using a Nikon A1R MP confocal microscope to include previously defined boundaries of medial agranular cortex (AGm; Ng et al., 2015) in both hemispheres throughout the entire thickness of each coronal brain section (z-stack imaging). The acquired z-stack images were saved at maximal projections as a 2D image for each coronal section and a 400 × 400 μm² subarea of AGm, extending to medial and dorsal pial boundaries (Figure 2), was selected in each hemisphere. Within the selected subarea, the number of immunofluorescently labeled parvalbumin-positive cells were counted in a blinded manner. For each brain, we combined core and peri-infarct sections (300 μm apart in rostral-caudal axis) and a cell was counted as positive if it had any immunofluorescent label for parvalbumin.

Statistical analysis
Data from motor tests were analyzed using two-way repeated measures analysis of variance (ANOVA) and followed by Dunnett’s post hoc test for multiple comparisons (GraphPad Prism 7.05 software, GraphPad Software Inc., La Jolla, CA, USA). For all other data, means from two experimental groups were compared using two-tailed Student’s t-test (paired t-test for body weight comparisons), and means from three or more groups using one-way ANOVA followed by Dunnett’s multiple comparisons test. A P-value < 0.05 was considered statistically significant. Expressed values are mean ± standard error.

Results

Running distance and speed
To mimic mild physical rehabilitation, all vehicle and drug-treated animals received access to a running wheel in their home cage for 2 hours daily, from post-stroke day 9 through completion of the study. Because of voluntary running, on average it took about 1 week (between post-stroke days 9 to 16) for vehicle-treated mice to gradually increase their covered distance and consistently run ~2 km per session/day (Figure 3A). On the contrary, it took about 2 weeks (post-stroke days 9 to 22) for drug-treated mice to reach consistent running (Figure 3A), however they covered shorter distance compared to vehicle-treated mice (Figure 3B). No significant difference was observed in the running speed of mice among experimental groups (Figure 3C). Notably, wheel running prevented body weight gain in experimental animals, except 10 mg/kg fluoxetine group (Figure 3D). Compared to baseline body weight values, high dose fluoxetine-treated mice recorded gain of ~3 g on post-stroke day 42, similar to “sham” and “stroke” groups.

Motor recovery in grid-walking test
To evaluate the effect of atomoxetine or fluoxetine, in combination with wheel running, on recovery of motor function after stroke, spontaneous motor behavior of the forelimb in gait was monitored in grid-walking test. As expected, focal cerebral stroke caused a significant and sustained deficit in the contralateral, i.e. affected, forelimb function of mice in the grid-walking test (Figure 4A; n = 12/group; group × day interaction F(10, 38) = 5.805, P < 0.0001). Within each stroke-affected experimental group, post hoc analyses with Dunnett’s correction revealed statistically significant differences in the affected forelimb function between baseline and corresponding post-stroke evaluation days (P = 0.0001). Within the sham group, no statistically significant difference was observed in the function of the affected forelimb between baseline and post-stroke evaluation days (P > 0.05). Gradual recovery of the impaired function was observed in all stroke-affected animals between post-stroke days 3 and 14, which continued improvement for higher dose atomoxetine and fluoxetine-treated mice, but plateaued for vehicle-treated group similar to observations by other
researchers (Birjandi et al., 2020; Trout et al., 2020). Within day comparisons of experimental groups (vehicle-treated vs others; post hoc analyses with Dunnett’s correction) showed statistically significant difference of the forelimb function only between vehicle and higher dose drug-treated mice on day 42 post-stroke (Figure 4B, $P = 0.007$ for 1 mg/kg atomoxetine, and $P = 0.011$ for 10 mg/kg fluoxetine). As expected, comparison of sham-operated and vehicle-treated mice also showed statistically significant difference of the forelimb function on all evaluation days ($P < 0.0001$) except the baseline ($P > 0.05$). Lastly, similar comparisons done for the ipsilateral, i.e. unaffected, forelimb did not reveal statistically significant difference between any of the groups on any of the evaluation days (Figure 4C, $P > 0.05$).

Motor recovery in cylinder test
For the same purpose, we used cylinder test to monitor spontaneous motor behavior of the forelimb in rearing. Similar to the grid-walking test, cylinder test revealed significant deficit in the function of the contralateral, i.e. stroke-affected, forelimb after stroke (Figure 5A; $n = 12$ group; group $\times$ day interaction $F_{(30,385)} = 9.572, P < 0.0001$). Post hoc analyses with Dunnett’s correction confirmed statistically significant differences between affected forelimb function at baseline and corresponding post-stroke evaluation days for each of stroke-affected experimental groups ($P < 0.001$). No statistically significant difference was observed in the function of the affected forelimb between baseline and any post-stroke evaluation day within the sham group ($P > 0.05$). Here too, gradual recovery of the impaired function was documented in all stroke-affected animals during the first 2 weeks post-stroke, which continued in higher dose drug-treated mice but plateaued at various degrees for others. Within day comparisons (vehicle-treated vs. other experimental groups; post hoc analyses with Dunnett’s correction) showed statistically significant difference of the forelimb function only between vehicle and higher dose drug-treated mice on day 42 post-stroke (Figure 5B, $P < 0.001$ for 1 mg/kg atomoxetine, and $P = 0.04$ for 10 mg/kg fluoxetine). Comparison of sham-operated and vehicle-treated mice also showed statistically significant difference of the forelimb function on all evaluation days ($P < 0.0001$) except the baseline ($P > 0.05$).

Correlation of molecular and cellular markers with motor function
In addition to functional outcomes, we evaluated three molecular and one molecular-cellular outcome measure of post-stroke motor recovery in experimental animals on day 42 post-stroke. For molecular outcome measures, the levels of regeneration-associated protein GAP-43, and synaptogenesis-associated proteins synaptophysin and PSD-95 were evaluated in protein lysates of peri-infarct cortical samples using western blotting and no significant differences were observed among experimental groups (data not shown). For the molecular-cellular outcome measure, the number of parvalbumin-positive neurons in medial premotor area (AGm) of ipsilateral and contralateral hemispheres was evaluated using immunofluorescence labeling. Our observations revealed visually apparent and statistically significant decrease in the number of parvalbumin-positive inhibitory interneurons in the ipsilateral AGm of higher dose drug-treated mice but not other experimental groups (Figure 2, $P < 0.001$).

Infarct location and volume
To evaluate the location of cerebral infarction and lesion volume on day 42 post-stroke, PFA-fixed brain sections of all experimental groups were stained with Cresyl violet, followed by histologic examination (Figure 6). As expected, cerebral infarction involved the primary motor cortex in all stroke-affected experimental groups. Volumetric measurements revealed no significant differences in the cerebral infarct volume among stroke-affected experimental groups (Figure 6; $P > 0.05$, 0.33–0.59 mm$^3$ average stroke volume).

Motor function in post-stroke mice treated with atomoxetine or fluoxetine alone
In a separate set of experiments where the effect of high dose atomoxetine or fluoxetine treatment alone (i.e. no wheel running) was evaluated on motor recovery, mice showed a sustained deficit in the stroke-affected forelimb function in the grid-walking test, however no statistically significant group by day interaction was documented (Figure 7A; $n = 7$ group; group $\times$ day interaction $F_{(10,90)} = 9.223, P = 0.032$). Within each experimental group, post hoc analyses with Dunnett’s correction revealed statistically significant differences in the affected forelimb function between baseline and corresponding post-stroke evaluation days ($P < 0.0001$). However, within day comparisons showed no significant difference in the stroke-affected forelimb function of vehicle vs. drug-treated animals (Figure 7A; $P > 0.05$). As expected, similar comparisons done for the unaffected forelimb did not reveal statistically significant difference between any of the groups on any of the evaluation days (Figure 7B, $P > 0.05$). Similarly, these animals showed significant deficit in the function of the stroke-affected forelimb in cylinder test (Figure 7C; $n = 7$ group; group $\times$ day interaction $F_{(10,90)} = 2.278, P = 0.0198$). Within experimental group comparisons revealed statistically significant difference in the affected forelimb function between baseline and corresponding post-stroke evaluation days ($P = 0.0001$). Whereas, within day comparisons revealed statistically significant difference only for high-dose atomoxetine vs vehicle-treated groups on day 14 ($P = 0.026$), indicating slightly worsened affected forelimb function in atomoxetine-treated animals (Figure 7C).

Discussion
It is generally accepted that higher intensity and earlier physical rehabilitation leads to better functional outcomes after stroke (Egan et al., 2014; Bernhardt et al., 2017a) by enhancing spontaneous endogenous plasticity and facilitating neural repair (Krakauer et al., 2012; Bernhardt et al., 2017a). Most of these endogenous neurorestorative mechanisms are activated a few days after stroke and peak within the first 2 weeks post-stroke, making physiotherapy and other potential therapeutic interventions especially effective during this time-window (Murphy and Corbett, 2009; Lenz et al., 2015; Carmichael, 2016). Because most stroke survivors are unable to meet the requirement of high-intensity and early rehabilitation, one potential approach to overcome this problem is through add-on pharmacological therapy aimed at prolonging the enhanced neuroplasticity of the post-stroke brain and/or enhancing the effects of lower-intensity physical rehabilitation (Ng et al., 2015; Carmichael, 2016). To expand on this idea, we evaluated the potential of atomoxetine and fluoxetine, in combination with wheel running as a form of physiotherapy, to promote motor recovery in adult male mice after ischemic stroke. Atomoxetine and fluoxetine enhance noradrenergic and serotonergic neurotransmission, and are indicated for treatment of ADHD and depression, respectively (Wong et al., 1995; Christman et al., 2004). Our rationale for focusing on these two neurotransmitter systems was because of a large body of literature indicating involvement of noradrenergic and serotonergic systems in modulation of brain plasticity, motor learning and memory (Tully and Bolshakov, 2010; Rossi, 2016; Borodovitsyna et al., 2017; Kraus et al., 2017). Although, there are other drug classes which enhance noradrenergic or serotonergic neurotransmission, we focused on reuptake inhibitors because of their high target selectivity and long history of clinical use (Lopez-Munoz and Alamo, 2009).

It is noteworthy, that there are several published experimental
studies which evaluated the effects of fluoxetine on post-stroke motor recovery in rodents and reported mixed results (Windle and Corbett, 2005; Ng et al., 2015; Sun et al., 2016; Hu et al., 2020). Two other experimental studies documented beneficial effect of fluoxetine on cognitive recovery after stroke (Li et al., 2009; Vahid-Ansari and Albert, 2018). One the contrary, we are unaware of a preclinical/basic study focusing on atomoxetine for post-stroke recovery.

In the current study, daily treatment with atomoxetine or fluoxetine started on post-stroke day 5, past the acute neuroprotective time-window and beginning of subchronic phase, and lasted until day 16 to include the period during which endogenous post-stroke brain plasticity is most active (Krackauer et al., 2012; Carmichael, 2016). Physiotherapy, which consisted of voluntary wheel running (2 hours/day, 6 days/week) in animal’s home cage, started on post-stroke day 9 and lasted until the end of the study. Post-stroke day 9 is comparable to the time when most stroke survivors start some degree of regular physical rehabilitation (the 2nd week), which however is likely delayed and suboptimal (Lay et al., 2016; Fini et al., 2017). Our rationale for combing drug treatment with physiotherapy was because of the standard of care in most developed countries, where majority of stroke survivors go through some type of physical rehabilitation (Winstein et al.,...
Figure 5  Enhanced motor recovery with atomoxetine or fluoxetine treatment in cylinder test. (A, B) Following photothrombotic stroke mice treated with atomoxetine or fluoxetine exhibited dose-dependent improvement in affected forelimb motor function (n = 12 per group). Compared to vehicle-treated group, mice treated with 1 mg/kg atomoxetine (P < 0.001) or 10 mg/kg fluoxetine (P = 0.04) showed statistically significantly improved motor function on day 42 after stroke (two-way repeated measures analysis of variance followed by Dunnett’s multiple comparison). Values are expressed as mean ± standard error. Atomo 0.3: 0.3 mg/kg atomoxetine; Atomo 1.0: 1.0 mg/kg atomoxetine; Fluox 3.0: 3 mg/kg fluoxetine; Fluox 10.0: 10 mg/kg fluoxetine.

Figure 6  Infarct location and volume. (A) Volumetric measurements of brain infarction did not reveal statistically significant differences among experimental groups on day 42 after stroke (n = 6 per group; one-way analysis of variance followed by Dunnett’s multiple comparison, P > 0.05). Values are expressed as mean ± standard error. (B) A representative Cresyl violet-stained mouse brain on day 42 after stroke, indicating location of infarction (outlined in red dotted line) in the primary motor cortex. Atomo 0.3: 0.3 mg/kg atomoxetine; Atomo 1.0: 1.0 mg/kg atomoxetine; Fluox 3.0: 3 mg/kg fluoxetine; Fluox 10.0: 10 mg/kg fluoxetine. Similar results were observed in the second cohort of experimental animals which received high dose drug treatments but no physical rehabilitation.

2016). Although, the practice of physical rehabilitation greatly varies among providers, the current recommendation for drug testing intended for post-stroke recovery is trending towards combination therapy with physical rehabilitation (Kwakkel et al., 2020).

It is noteworthy, that both atomoxetine and fluoxetine affected voluntary running of animals. Mice treated with either drug covered shorter distance in comparison to the vehicle-treated group, despite similarities in their speed of running. This effect was especially evident during daily drug treatments (post-stroke days 9 to 16), after which the difference gradually dissipated. Notably, our results are in line with earlier observations indicating decreased locomotion/running of experimental animals in the result of chronic atomoxetine or fluoxetine treatment (Klenotich et al., 2012; Moon et al., 2014).

The daily average distance ran by animals in our study was 1.5–2 km during the 2-hour rehabilitation period, which is 5 to 10-fold shorter compared to the distance ran by mice with overnight access to the wheels (Karamyan Al-Shoyaib, unpublished observations). This amount of physical activity prevented body weight gain in all experimental groups, except 10 mg/kg fluoxetine-treated animals, which gained ~3.0 g over the course of our study, similar to “sham” and “stroke” groups. Higher-dose atomoxetine-treated animals also gained weight throughout the study (~1.2 g), however it was not at a statistically significant level. Although, food consumption of the animals was not measured in our study, we speculate that the observed weigh gain in high dose drug-treated animals has to do with shorter distance of running during the first 3 weeks of the study.

In our study, functional recovery of motor control was determined in two tasks of spontaneous motor behaviors of the forelimb, one during gait (grid-walking test) and another during exploratory rearing (cylinder test). Both tests revealed dose-dependent potential of atomoxetine and fluoxetine to enhance motor recovery by day 42 post-stroke, while atomoxetine being more potent considering its lower effective dose. Importantly, limited amount of wheel running alone was insufficient to promote motor recovery in mice, but was critical to augment the effect of high dose atomoxetine or fluoxetine. Likewise, high-dose drug treatments alone were insufficient to enhance functional recovery in the experimental animals. This synergetic effect of drug treatment plus physiotherapy is of great interest, and our ongoing pharmacological, molecular-genetic and biochemical studies should provide details about the molecular mechanism(s) responsible for this observation. It is unlikely that one mechanism is responsible for the observed effects, but rather multiple mechanisms involving enhanced axonal sprouting and synaptogenesis, angiogenesis and neurogenesis are likely involved it the observed effects. Notably, these processes are intertwined and inherently linked to neural repair and post-stroke recovery (Carmichael, 2016). Physical exercise (Christie et al., 2008; van Praag, 2008; Liu and Nussslock, 2018) as well as noradrenergic (Marzo et al., 2009; Tully and Bolshakov, 2010) and serotonergic (Lesch and Waider, 2012; Sobrido-Camean et al., 2018) neurotransmission are well-known to modulate these processes. Furthermore, fluoxetine has been shown to potentiate brain plasticity processes upon continuous use in numerous experimental studies (Levy et al., 2019; Song et al., 2019; Steinzeig et al., 2019), and there is some evidence for similar effects with chronic treatment of atomoxetine (Fumagalli et al., 2010; Pina et al., 2020).

In this study, we also evaluated the expression levels of GAP-43, synaptophysin, and PSD-95 in the peri-infarct cortical
samples of experimental animals collected on post-stroke day 42. These molecular targets maybe causally associated with neural repair mechanisms (Wang et al., 2019), however, we did not observe significant differences in their expression levels among experimental groups (data not shown). In addition, we evaluated the number of parvalbumin-expressing neurons in the AGm area (medial premotor cortex) of ipsi- and contralateral hemispheres of the experimental animals. Parvalbumin-expressing neurons in AGm are primarily GABAergic inhibitory interneurons, and their reduced excitability and/or number is causally linked to motor learning and functional recovery after stroke (Zeiler et al., 2013; Ng et al., 2013). Notably, our results are in line with these observations indicating statistically significant reduction of parvalbumin-expressing neurons in ipsilateral AGm area of high-dose atomoxetine or fluoxetine-treated animals but not other experimental groups.

It is noteworthy, that fluoxetine has been used in several clinical trials for stroke recovery, including well-publicized FLAME (FLuoxetine on motor rehabilitation After ischeMic stroKE) and FOCUS (Fluoxetine Or Control Under Supervision) trials (Chollet et al., 2011; Collaboration, 2019). FLAME study suggested that fluoxetine improves motor recovery in post-stroke patients, whereas FOCUS study found no significant difference in motor recovery of patients receiving fluoxetine and placebo. Among notable differences in these two clinical trials, which, in our opinion, are the likely reasons for the conflicting results are the lack of regular physical rehabilitation and use of a less rigorous/quantitative method (i.e., modified Rankin scale) for functional assessment of patients in FOCUS study. Unfortunately, a very similar study design and the same deficiencies were present in newly completed Assessment of FluoxetineIn Ne In Stroke recoveryY (AFFINITY) (Collaboration, 2020a) and Efficacy of Fluoxetine—a randomised Controlled Trial in Stroke (EFFECTS) (Collaboration, 2020b) clinical trials, which again did not find beneficial effects of fluoxetine therapy for post-stroke recovery.

The relevance of our study to these contradicting reports is the finding that combination of fluoxetine with physical rehabilitation is necessary for motor recovery of mice after stroke. In fact, in addition to FLAME trial, two smaller and less publicized clinical studies also combined fluoxetine therapy with physical rehabilitation and documented improved motor function in stroke patients (Guo et al., 2016; Asadollahi et al., 2018). Collectively, our observations and the results of these clinical studies highlight the main deficiency of FOCUS, AFFINITY and EFFECTS trials, and suggest the need for combining fluoxetine therapy with physical rehabilitation in a future large clinical trial, before moving away from this drug (Kwakkel et al., 2020).

Contrary to fluoxetine, little is known about atomoxetine in a stroke setting. Only two pilot studies with handful of stroke patients were conducted so far, reporting improvement of motor function with atomoxetine therapy (Kinoshita et al., 2011; Varagut et al., 2017), whereas another study reported improvement of post-stroke aphasia with atomoxetine therapy (Yamada et al., 2016).

In summary, our results indicate that pharmacological modulation of noradrenergic or serotonergic systems with atomoxetine and fluoxetine, in combination with limited voluntary running, promotes motor recovery in mice after ischemic stroke. This is the first study to document the potential of atomoxetine to facilitate post-stroke functional recovery in a pre-clinical setting. Our observations point out that enhanced noradrenergic neurotransmission by atomoxetine is likely more effective in facilitating post-stroke recovery than enhanced serotonergic neurotransmission by fluoxetine. This question is a subject of our ongoing research, which also aims to reveal the molecular signaling pathways and potential link between these two neurotransmitter systems in mechanisms related to functional recovery after stroke. Importantly, several published studies suggest that norepinephrine maybe more central in modulating neural repair mechanisms than serotonin. For example, norepinephrine but not serotonin appears to directly activate neural precursor cells (Jhaveri et al., 2010) and modulate long-term potentiation (Stanton and Survev, 1985). Another study suggested that noradrenergic neurotransmission maybe involved in noradrenergic and serotonergic axonal regeneration, whereas serotonergic neurotransmission only for serotonergic axonal regrowth (Liu et al., 2003). Last, one more study demonstrated that exercise-induced BDNF upregulation is modulated by noradrenergic but not serotonergic neurotransmission (Garica et al., 2003).

It is noteworthy, that our study has key limitations, including the use of adult male but not female and older animals, a need to determine the optimal time-window of pharmacotherapy and whether physiotherapy should be continuous to maintain improved function, and extension of studies beyond 6 weeks. Another important question to address experimentally is the extent of physiotherapy, i.e. its threshold, below which the added pharmacotherapy does not promote functional recovery. If further validated in larger studies, our observations suggest that add-on atomoxetine or fluoxetine therapy coupled with limited physical rehabilitation could offer therapeutic modality for stroke survivors who have difficulty to engage in early, high-intensity physiotherapy.

Author contributions: FFA, AAS, NS, SI and VTK performed the experiments. FFA, AAS, NS, AP and VTK analyzed data. STK and TVA helped with concept and methodology development and interpretation of data. VTK conceived the study. FFA and VTK wrote the paper. All authors revised and approved the manuscript.

Conflicts of Interest: The authors declare no commercial conflict of interest.

Financial support: This work was partly supported by a National Institutes of Health Research Grant to VTK (1R01NS106879).

Institutional review board statement: This study was approved by the Texas Tech University Health Sciences Center Institutional Animal Care and Use Committee (protocol # 16019).

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Data sharing statement: Datasets analyzed during the current study are available from the corresponding author on reasonable request.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References
Al Shoyab A, Archie SR, Karayaman VT (2019) Intraperitoneal route of drug administration: should it be used in experimental animal studies? Pharm Res 37:12.
Alamri FF, Shoyaib AA, Biggers A, Upham L, Suido NN, Karayaman VT (2018) Applicability of the grip strength and automated von Frey tactile sensitivity tests in the mouse photomotographic model of stroke. Behav Brain Res 336:250-255.
Asadollahi M, Ramezani M, Khammaroddini, Karmalivjeh V (2018) The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clin Rehabil 32:1069-1075.
Bernhardt J, Goddeck E, Johnson L, Langhorn P (2017a) Early rehabilitation after stroke. Curr Opin Neurol 30:48-54.
Bernhardt J, Hayward KS, Kwakkel G, Ward NS, Wolf SL, Borschmann K, Kosaaker JW, Boyd LA, Carmichael ST, Corbett D, Cramer SC (2017b) Agreed definitions and a shared vision for new standards in stroke recovery research: The Stroke Recovery and Rehabilitation Roundtable taskforce. Int J Stroke 12:444-450.
Bernhardt J, Borschmann K, Boyd L, Thomas Carmichael S, Corbett D, Cramer SC, Hoffmann T, Kwakkel G, Savitz SI, Saposnik G, Walker M, Ward N (2016) Moving rehabilitation research forward: Developing consensus statements for rehabilitation and recovery research. Int J Stroke 11:454-458.
Bernhardt J, Hayward KS, Dancause N, Lannin NA, Ward NS, Nudo RJ, Farrin A, Churilov L, Boyd LA, Jones TA, Carmichael ST, Corbett D, Cramer SC (2019) A stroke recovery trial demonstration framework: Conceptualized core recommendations from the Second Stroke Recovery and Rehabilitation Roundtable. Int J Stroke 14:792-802.
Bjorndal SJ, Abdulljawad N, Nair S, Dehghani M, Suzuki K, Kimura H, Carmichael ST (2020) Phosphodiesterase 10A inhibition leads to brain region-specific specificity based on stroke type. Transl Stroke Res doi: 10.1007/s12975-020-00819-8.
Lesch KP, Waider J (2012) Serotonin in the modulation of neural plasticity and networks: the implications for neurodevelopmental disorders. Neuron 76:175-191.

Ledbetter M (2006) Atomoxetine: a novel treatment for child and adult ADHD. Neuropsychopharmacology 31:1493-1513.

Lay S, Bernhardt J, West T, Churilov L, Dart A, Hayes K, Cumming TB (2016) Is early rehabilitation and recovery of function after stroke related to set the threshold of neural plasticity toward therapy. Neural Regen Res 10:1537-1540.

Lev M, Melamed E, Assaf Y, Abramovich A, Isacson O, Kuchelmeister K, Silver J (2016) Therapeutic administration of amotrexone combined with rTMS and occupational therapy for upper limb hemiparesis after stroke: a case series study of three patients. Acta Neurol Belg 116:31-37.

Lennard S, Siegel MP, McCormick MS, Roitman JD, Karamyan VT (2019) Identification of membrane-bound variant of metallocendopeptidase neurilysin (EC 3.4.24.16) as the non-angiotensin type 1 (Non-AT1), Non-AT2 angiotensin binding protein (NABP) in rodents. Mol Cell Endocrinol 50:3663-3673.

Lentz MP, Waider J (2012) Serotonin in the modulation of neural plasticity and networks: implications for neurodevelopmental disorders. Neuropsychopharmacology 37:1620-1631.

Li WL, Cai HH, Wang B, Chen L, Zhou QG, Luo CX, Liu N, Ding XS, Zhu DY (2009) Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. J Neurosci Res 87:112-122.

Lin PZ, Nusslock R (2018) Exercise and chronic neurological repair. Nat Rev Neurosci 19:675-690.

Liu Y, Iida H, Shindoh K, Nakamura S (2003) Interaction between serotoninetic and noradrenergic neurons during development. Exp Neurol 184:169-178.

Lopez-Munoz F, Alamo C (2009) Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 15:1563-1586.

Marzo A, Bai J, Otani S (2009) Neuroplasticity regulation by noradrenaline in mammalian brain. Curr Neuropharmacol 7:286-295.

Moon SJ, Kim CJ, Lee YI, Hong M, Han J, Bahn GH (2014) Effect of atomoxetine on cognitive function in a mouse model of attention-deficit/hyperactivity disorder (ADHD). PLoS ONE 9:e108198.

Murphy TH, Corbett D (2009) Plasticity during stroke recovery: from synapse to network. Nat Rev Neurosci 10:672-686.

Ng KL, Gibson EM, Hubbard R, Yang J, Caffo B, O'Brien RJ, Krajer JW, Zeler SR (2015) Fluoxetine maintains a state of heightened responsiveness to motor training early after stroke in a mouse model of deficit. Neuropsychopharmacology 40:1379-1385.

Nicholson S, Sniethoff FV, van Wijk F, Greg CA, Johnston M, McMurdie ME, Dennis M, Mead GE (2013) A systematic review of perceived barriers and motivators to physical activity after stroke. Int J Stroke 8:357-366.

Pina R, Rozas C, Contreras D, Hardy P, Urgante G, Zeise ML, Rojas P, Morales B (2020) Atomoxetine reestablishes long term potentiation in a mouse model of attention deficit/hyperactivity disorder. Neurosci 439:268-274.

Rashid M, Wangler NJ, Yang L, Shah K, Arumugam TV, Abbaschian TJ, Karamyan VT (2014) Functional up-regulation of endopeptidase neuropilin during post-acute and early recovery phases of experimental stroke in mouse brain. J Neurochem 129:179-189.

Reihe A, Barraco A, Doneda P (2004) Fluoxetine: a review on evidence based medicine. Ann Hyg 8:321-326.

Richard MP (2016) Analysis of the fluoxetine-induced plasticity mechanisms as a strategy for understanding plasticity related neural disorders. Neurosci Res 115:547-548.

Sobrido-Carameen D, Rodicio CM, Barreiro-Iglesias A (2018) Serotonin controls axon regeneration and long-term recovery after spinal cord injury in male rats. J Neurosci 38:1493-1499.

Song T, Wu H, Li R, Hu X, Rao G, Liu Y, Lei H (2019) Repeated fluoxetine treatment induces better behavioral recovery in rats. Long-lasting neurogenesis changes in the medial prefrontal cortex of adult rats. Behav Brain Res 365:114-124.

Stanton PK, Darley JV (1985) Depletion of norepinephrine, but not serotonin, reduces spatial term potentiation in the dentate gyrus of rat hippocampal slices. J Neurosci 5:2169-2176.

Steinzeit A, Camarazzo C, Castren E (2019) Fluoxetine-induced plasticity in the visual cortex shortens the duration of the naturally occurring critical period. Eur J Neurosci 50:3663-3673.

Sun X, Zhou Z, Liu Z, Zhao M, Zhao S, Xiao T, Joilkinson J, Zhao C (2016) Fluoxetine prevents neurogenesis in rats with cortical infarcts, but this is not reflected in a behavioral recovery. J Mol Neurosci 58:233-242.

Synera N, Alami FF, Jayaraman S, Lee F, Karamyan ST, Arumugam TV, Karamyan VT (2019) Atomoxetine deficit in the mouse model of chronic ischemic distal middle cerebral artery occlusion model of stroke. Behav Brain Res 380:1124-1128.

Trout AL, Kahle MP, Roberts JM, Marcelo A, de Hoog L, Boychuk JG, Grupke SL, Berretta A, Gawak EG, Boychuk CR, Gorman AA, Edwards DN, Rutkai I, Bose I, Ushiba I, Ueda H, Ibara M, Smith BN, Carlson AK, Bix GJ (2020) Perlecan domain-V enhances neurogenic brain repair after stroke in mice. Transl Stroke Res doi: 10.1007/s12975-020-00880-5.

Tintou M, Damalakas K, Makris N (2020) Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans. Neuromolecular Med 12:294-310.

Tintou M, Damalakas K, Makris N (2020) Central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans. Neuromolecular Med 12:294-310.

Tintou M, Damalakas K, Makris N (2020) Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans. Neuromolecular Med 12:294-310.

Tintou M, Damalakas K, Makris N (2020) Central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans. Neuromolecular Med 12:294-310.

Tintou M, Damalakas K, Makris N (2020) Central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans. Neuromolecular Med 12:294-310.

Tintou M, Damalakas K, Makris N (2020) Central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans. Neuromolecular Med 12:294-310.

Tintou M, Damalakas K, Makris N (2020) Central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans. Neuromolecular Med 12:294-310.